{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:59:09Z","timestamp":1791593949527,"version":"4.3.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40262-025-01507-2","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T18:31:31Z","timestamp":1747852291000},"page":"999-1046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations: A Systematic Review"],"prefix":"10.1007","volume":"64","author":[{"given":"Femke A.","family":"Elzinga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R. V.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onno W.","family":"Akkerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Rottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"van der Vaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard H.","family":"Koppelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3551-1201","authenticated-orcid":false,"given":"Paola","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"issue":"3","key":"1507_CR1","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jcf.2023.01.005","volume":"22","author":"D Purkayastha","year":"2023","unstructured":"Purkayastha D, Agtarap K, Wong K, Pereira O, Co J, Pakhale S, Kanji S. Drug\u2013drug interactions with CFTR modulator therapy in cystic fibrosis: focus on Trikafta\u00ae\/Kaftrio\u00ae. J Cyst Fibrosis. 2023;22(3):478\u201383. https:\/\/doi.org\/10.1016\/j.jcf.2023.01.005.","journal-title":"J Cyst Fibrosis"},{"issue":"74","key":"1507_CR2","doi-asserted-by":"publisher","first-page":"74ra24","DOI":"10.1126\/scitranslmed.3001868","volume":"3","author":"LS Ostedgaard","year":"2011","unstructured":"Ostedgaard LS, Meyerholz DK, Chen JH, Pezzulo AA, Karp PH, Rokhlina T, Ernst SE, Hanfland RA, Reznikov LR, Ludwig PS, Rogan MP, Davis GJ, Dohrn CL, Wohlford-Lenane C, Taft PJ, Rector MV, Hornick E, Nassar BS, Samuel M, Zhang Y, Stoltz DA. The \u0394F508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs. Sci Transl Med. 2011;3(74):74ra24. https:\/\/doi.org\/10.1126\/scitranslmed.3001868.","journal-title":"Sci Transl Med"},{"issue":"33\u201334","key":"1507_CR3","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3238\/arztebl.2017.0564","volume":"114","author":"S Naehrig","year":"2017","unstructured":"Naehrig S, Chao CM, Naehrlich L. Cystic fibrosis. Dtsch Arztebl Int. 2017;114(33\u201334):564\u201374. https:\/\/doi.org\/10.3238\/arztebl.2017.0564.","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"1507_CR4","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.3390\/ijms24044052","volume":"24","author":"C Yu","year":"2023","unstructured":"Yu C, Kotsimbos T. Respiratory infection and inflammation in cystic fibrosis: a dynamic interplay among the host, microbes, and environment for the ages. Int J Mol Sci. 2023;24(4):4052. https:\/\/doi.org\/10.3390\/ijms24044052.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1507_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/jor2020005","volume":"2","author":"M Mergiotti","year":"2022","unstructured":"Mergiotti M, Murabito A, Prono G, Ghigo A. CFTR modulator therapy for rare CFTR mutants. J Respir Med. 2022;2(2):59\u201376. https:\/\/doi.org\/10.3390\/jor2020005.","journal-title":"J Respir Med"},{"issue":"7","key":"1507_CR6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/bph.15709","volume":"179","author":"J Liu","year":"2022","unstructured":"Liu J, Berg AP, Wang Y, Jantarajit W, Sutcliffe KJ, Stevens EB, Cao L, Pregel MJ, Sheppard DN. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR. Br J Pharmacol. 2022;179(7):1319\u201337. https:\/\/doi.org\/10.1111\/bph.15709.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1507_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S2213-2600(12)70057-7","volume":"1","author":"MP Boyle","year":"2013","unstructured":"Boyle MP, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med. 2013;1(2):158\u201363. https:\/\/doi.org\/10.1016\/S2213-2600(12)70057-7.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1507_CR8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","volume":"14","author":"L Allen","year":"2023","unstructured":"Allen L, Allen L, Carr SB, Davies G, Downey D, Egan M, Forton JT, Gray R, Haworth C, Horsley A, Smyth AR, Southern KW, Davies JC. Future therapies for cystic fibrosis. Nat Commun. 2023;14(1):693. https:\/\/doi.org\/10.1038\/s41467-023-36244-2.","journal-title":"Nat Commun"},{"key":"1507_CR9","unstructured":"Cystic Fibrosis Foundation. 2023 patient registry annual data report. http:\/\/www.cff.org\/medical-professionals\/patient-registry. Assessed on 6 Mar 2025."},{"issue":"9","key":"1507_CR10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46228","volume":"15","author":"AI Santos","year":"2023","unstructured":"Santos AI, Pacheco J, Cemlyn-Jones J, Gamboa F. Triple therapy for cystic fibrosis (elexacaftor, tezacaftor, and ivacaftor): desensitization after skin rash. Cureus. 2023;15(9): e46228. https:\/\/doi.org\/10.7759\/cureus.46228.","journal-title":"Cureus"},{"issue":"10212","key":"1507_CR11","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS, VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8.","journal-title":"Lancet"},{"key":"1507_CR12","unstructured":"Highlights of prescribing information of Trikafta. https:\/\/pi.vrtx.com\/files\/uspi_vanzacaftor_tezacaftor_deutivacaftor.pdf. Assessed on 6 Mar 2025."},{"issue":"4","key":"1507_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2165\/00003088-199835040-00004","volume":"35","author":"E Rey","year":"1998","unstructured":"Rey E, Tr\u00e9luyer JM, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet. 1998;35(4):313\u201329. https:\/\/doi.org\/10.2165\/00003088-199835040-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1507_CR14","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jhep.2004.08.006","volume":"41","author":"T Lamireau","year":"2004","unstructured":"Lamireau T, Monnereau S, Martin S, Marcotte JE, Winnock M, Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol. 2004;41(6):920\u20135. https:\/\/doi.org\/10.1016\/j.jhep.2004.08.006.","journal-title":"J Hepatol"},{"issue":"3","key":"1507_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1148\/radiographics.20.3.g00ma08767","volume":"20","author":"LJ King","year":"2000","unstructured":"King LJ, Scurr ED, Murugan N, Williams SG, Westaby D, Healy JC. Hepatobiliary and pancreatic manifestations of cystic fibrosis: MR imaging appearances. Radiographics. 2000;20(3):767\u201377. https:\/\/doi.org\/10.1148\/radiographics.20.3.g00ma08767.","journal-title":"Radiographics"},{"key":"1507_CR16","unstructured":"Highlights of prescribing information of Kalydeco. https:\/\/pi.vrtx.com\/files\/uspi_ivacaftor.pdf. Assessed on 6 Mar 2025."},{"key":"1507_CR17","unstructured":"Highlights of prescribing information of Orkambi. https:\/\/pi.vrtx.com\/files\/uspi_lumacaftor_ivacaftor.pdf. Assessed on 6 Mar 2025."},{"key":"1507_CR18","unstructured":"Highlights of prescribing information of Symdeko. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210491lbl.pdf. Assessed on 6 Mar 2025."},{"key":"1507_CR19","doi-asserted-by":"publisher","first-page":"1274303","DOI":"10.3389\/fmed.2023.1274303","volume":"10","author":"P Ripani","year":"2023","unstructured":"Ripani P, Mucci M, Pantano S, Di Sabatino M, Collini F, Ferri G, Romano M, Recchiuti A. Maternal, newborn and breast milk concentrations of elexacaftor\/tezacaftor\/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy. Front Med. 2023;10:1274303. https:\/\/doi.org\/10.3389\/fmed.2023.1274303.","journal-title":"Front Med"},{"key":"1507_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fphar.2014.00065","volume":"5","author":"MM Costantine","year":"2014","unstructured":"Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014;5:65. https:\/\/doi.org\/10.3389\/fphar.2014.00065.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1507_CR21","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157\u201367. https:\/\/doi.org\/10.1056\/NEJMra035092.","journal-title":"N Engl J Med"},{"key":"1507_CR22","unstructured":"\u201cPRISMA.\u201d [Online]. https:\/\/www.prisma-statement.org. Accessed 20 Jun 2022."},{"key":"1507_CR23","unstructured":"\u201cPROSPERO.\u201d [Online]. https:\/\/www.crd.york.ac.uk\/prospero\/#searchadvanced. Accessed 20 Jun 2024."},{"key":"1507_CR24","unstructured":"\u201cWebPlotDigitizer.\u201d [Online]. https:\/\/automeris.io. Accessed on 9 Jul 2024."},{"issue":"1","key":"1507_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","volume":"208","author":"JL Goralski","year":"2023","unstructured":"Goralski JL, Hoppe JE, Mall MA, McColley SA, McKone E, Ramsey B, Rayment JH, Robinson P, Stehling F, Taylor-Cousar JL, Tullis E, Ahluwalia N, Chin A, Chu C, Lu M, Niu T, Weinstock T, Ratjen F, Rosenfeld M. Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med. 2023;208(1):59\u201367. https:\/\/doi.org\/10.1164\/rccm.202301-0084OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1507_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2024.102301","volume":"86","author":"NR Rose","year":"2024","unstructured":"Rose NR, Chalamalla AR, Garcia BA, Krick S, Bergeron J, Sadeghi H, Schellhase DE, Ryan KJ, Dowell AE, Acosta EP, Guimbellot JS. Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. Pulm Pharmacol Ther. 2024;86: 102301. https:\/\/doi.org\/10.1016\/j.pupt.2024.102301.","journal-title":"Pulm Pharmacol Ther"},{"issue":"6","key":"1507_CR27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s13318-022-00791-8","volume":"47","author":"L Viswanathan","year":"2022","unstructured":"Viswanathan L, Bachman E, Tian S, Ahluwalia N, Zhang Y, Bernstein HS, Panorchan P. Phase 1 study to assess the safety and pharmacokinetics of elexacaftor\/tezacaftor\/ivacaftor in subjects without cystic fibrosis with moderate hepatic impairment. Eur J Drug Metab Pharmacokinet. 2022;47(6):817\u201325. https:\/\/doi.org\/10.1007\/s13318-022-00791-8.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"1507_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clinthera.2023.11.003","volume":"46","author":"SEM Vonk","year":"2024","unstructured":"Vonk SEM, Lub R, Weersink EJM, Beuers U, Math\u00f4t RAA, Kemper EM, Altenburg J, Amsterdam Mucociliary Clearance Disease Research Group. Stepwise introduction of elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and liver cirrhosis Child-Pugh A or B using clinical and therapeutic drug monitoring: a case series. Clin Ther. 2024;46(2):154\u20138. https:\/\/doi.org\/10.1016\/j.clinthera.2023.11.003.","journal-title":"Clin Ther"},{"key":"1507_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2024.03.010","author":"SEM Vonk","year":"2024","unstructured":"Vonk SEM, Altenburg J, Math\u00f4t RAA, Kemper EM, Amsterdam Mucociliary Clearance Disease (AMCD) Research Group. Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor. J Cyst Fibros. 2024. https:\/\/doi.org\/10.1016\/j.jcf.2024.03.010.","journal-title":"J Cyst Fibros"},{"issue":"12","key":"1507_CR30","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","volume":"203","author":"ET Zemanick","year":"2021","unstructured":"Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, McColley SA, et al. A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med. 2021;203(12):1522\u201332. https:\/\/doi.org\/10.1164\/rccm.202102-0509OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1507_CR31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/phar.2786","volume":"43","author":"E Hong","year":"2023","unstructured":"Hong E, Li R, Shi A, Almond LM, Wang J, Khudari AZ, Haddad S, Sislyan S, Angelich M, Chung PS, Rao AP, Beringer PM. Safety of elexacaftor\/tezacaftor\/ivacaftor dose reduction: mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series. Pharmacotherapy. 2023;43(4):291\u20139. https:\/\/doi.org\/10.1002\/phar.2786.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"1507_CR32","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/cpt.2585","volume":"111","author":"E Hong","year":"2022","unstructured":"Hong E, Almond LM, Chung PS, Rao AP, Beringer PM. Physiologically-based pharmacokinetic-led guidance for patients with cystic fibrosis taking elexacaftor\u2013tezacaftor\u2013ivacaftor with nirmatrelvir\u2013ritonavir for the treatment of COVID-19. Clin Pharmacol Ther. 2022;111(6):1324\u201333. https:\/\/doi.org\/10.1002\/cpt.2585.","journal-title":"Clin Pharmacol Ther"},{"key":"1507_CR33","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Product quality review. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212273Orig1s000ChemR.pdf. Assessed 11 Oct 2024."},{"key":"1507_CR34","unstructured":"European Medicines Agency. Committee for Human Medical Products. Product information Kaftrio. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kaftrio-epar-product-information_en.pdf. Accessed 29 Jun 2024."},{"key":"1507_CR35","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Multi-disciplinary review and evaluation TRIKAFTA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212273Orig1s000MultidisciplineR.pdf. Accessed 29 Jun 2024."},{"key":"1507_CR36","unstructured":"DrugBank Online. Elexacaftor: uses, interactions, mechanism of action. https:\/\/go.drugbank.com\/drugs\/DB15444. Assessed 11 Oct 2024."},{"issue":"6","key":"1507_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","volume":"37","author":"SN de Wildt","year":"1999","unstructured":"de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37(6):485\u2013505. https:\/\/doi.org\/10.2165\/00003088-199937060-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1507_CR38","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40262-023-01342-3","volume":"63","author":"N Bouazza","year":"2024","unstructured":"Bouazza N, Urien S, Foissac F, Choupeaux L, Lui G, Froelicher Bournaud L, Rouillon S, Zheng Y, Bardin E, Stremler N, Bessaci K, Bihouee T, Coirier-Duet E, Marguet C, Deneuville E, Laurans M, Reix P, Gerardin M, Mittaine M, Epaud R, Thumerelle C, Weiss L, Berthaud R, Semeraro M, Treluyer JM, Benaboud S, Sermet-Gaudelus I. Lumacaftor\/ivacaftor population pharmacokinetics in pediatric patients with cystic fibrosis: a first step toward personalized therapy. Clin Pharmacokinet. 2024;63(3):333\u201342. https:\/\/doi.org\/10.1007\/s40262-023-01342-3.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1507_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","volume":"4","author":"JC Davies","year":"2016","unstructured":"Davies JC, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Robertson S, Green Y, Cooke J, Rosenfeld M, KIWI Study Group. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2\u20135 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016;4(2):107\u201315. https:\/\/doi.org\/10.1016\/S2213-2600(15)00545-7.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"1507_CR40","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","volume":"203","author":"JC Davies","year":"2021","unstructured":"Davies JC, Wainwright CE, Sawicki GS, Higgins MN, Campbell D, Harris C, Panorchan P, Haseltine E, Tian S, Rosenfeld M. Ivacaftor in infants aged 4 to < 12 months with cystic fibrosis and a gating mutation: results of a two-part phase 3 clinical trial. Am J Respir Crit Care Med. 2021;203(5):585\u201393. https:\/\/doi.org\/10.1164\/rccm.202008-3177OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"1507_CR41","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1002\/ppul.26093","volume":"57","author":"JS Guimbellot","year":"2022","unstructured":"Guimbellot JS, Ryan KJ, Anderson JD, Parker KL, Odom LV, Rowe SM, Acosta EP. Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis. Pediatr Pulmonol. 2022;57(11):2745\u201353. https:\/\/doi.org\/10.1002\/ppul.26093.","journal-title":"Pediatr Pulmonol"},{"key":"1507_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.577263","volume":"12","author":"PO Hanafin","year":"2021","unstructured":"Hanafin PO, Sermet-Gaudelus I, Griese M, Kappler M, Ellemunter H, Schwarz C, Wilson J, Tan M, Velkov T, Rao GG, Schneider-Futschik EK. Insights into patient variability during ivacaftor-lumacaftor therapy in cystic fibrosis. Front Pharmacol. 2021;12: 577263. https:\/\/doi.org\/10.3389\/fphar.2021.577263.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1507_CR43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jcf.2024.03.012","volume":"23","author":"P McNally","year":"2024","unstructured":"McNally P, Singh A, McColley SA, Davies JC, Higgins M, Liu M, Lu J, Rodriguez-Romero V, Shih JL, Rosenfeld M, VX15-770-124 Study Group. Safety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosis. J Cyst Fibros. 2024;23(3):429\u201335. https:\/\/doi.org\/10.1016\/j.jcf.2024.03.012.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"1507_CR44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","volume":"7","author":"JJ McNamara","year":"2019","unstructured":"McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2\u20135 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet Respir Med. 2019;7(4):325\u201335. https:\/\/doi.org\/10.1016\/S2213-2600(18)30460-0.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"1507_CR45","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","volume":"206","author":"JH Rayment","year":"2022","unstructured":"Rayment JH, Asfour F, Rosenfeld M, Higgins M, Liu L, Mascia M, Paz-Diaz H, Tian S, Zahigian R, McColley SA. A phase 3, open-label study of lumacaftor\/ivacaftor in children 1 to less than 2 years of age with cystic fibrosis homozygous for F508del-CFTR. Am J Respir Crit Care Med. 2022;206(10):1239\u201347. https:\/\/doi.org\/10.1164\/rccm.202204-0734OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"1507_CR46","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","volume":"6","author":"M Rosenfeld","year":"2018","unstructured":"Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, Tian S, Schneider J, Cunningham S, Davies JC, ARRIVAL study group. Ivacaftor treatment of cystic fibrosis in children aged 12 to < 24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med. 2018;6(7):545\u201353. https:\/\/doi.org\/10.1016\/S2213-2600(18)30202-9.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"1507_CR47","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jcf.2018.05.009","volume":"17","author":"A Trimble","year":"2018","unstructured":"Trimble A, McKinzie C, Terrell M, Stringer E, Esther CR Jr. Measured fetal and neonatal exposure to lumacaftor and ivacaftor during pregnancy and while breastfeeding. J Cyst Fibros. 2018;17(6):779\u201382. https:\/\/doi.org\/10.1016\/j.jcf.2018.05.009.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"1507_CR48","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jcf.2022.11.008","volume":"22","author":"R van der Meer","year":"2023","unstructured":"van der Meer R, Wilms EB, Eggermont MN, Paalvast HM, van Rossen RCJM, Heijerman HGM. The influence of exocrine pancreatic function on the exposure and pharmacokinetics of ivacaftor in people with cystic fibrosis. J Cyst Fibros. 2023;22(3):564\u20139. https:\/\/doi.org\/10.1016\/j.jcf.2022.11.008.","journal-title":"J Cyst Fibros"},{"issue":"5","key":"1507_CR49","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/psp4.12802","volume":"11","author":"X Pan","year":"2022","unstructured":"Pan X, Rowland YK. Addressing drug safety of maternal therapy during breastfeeding using physiologically-based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol. 2022;11(5):535\u20139. https:\/\/doi.org\/10.1002\/psp4.12802.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1507_CR50","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review Kalydeco (ivacaftor). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203188Orig1s000ClinPharmR.pdf. Accessed 29 Jun 2024."},{"key":"1507_CR51","unstructured":"European Medicines Agency. Committee for Human Medical Products. Product information Orkambi (lumacaftor\/ivacaftor). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orkambi-epar-product-information_en.pdf. Accessed 29 Jun 2024."},{"key":"1507_CR52","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review Symdeko (tezacaftor\/ivacaftor). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210491Orig1s000ClinPharmR.pdf. Accessed 29 Jun 2024."},{"key":"1507_CR53","unstructured":"European Medicines Agency. Committee for Human Medical Products. Product information Kalydeco (ivacaftor). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kalydeco-epar-product-information_en.pdf. Accessed 29 Jun 2024."},{"key":"1507_CR54","unstructured":"European Medicines Agency. Committee for Human Medical Products. Product information Symkevi (tezacaftor\/ivacaftor). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/symkevi-epar-product-information_en.pdf. Accessed 29 Jun 2024."},{"key":"1507_CR55","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review Orkambi (lumacaftor\/ivacaftor). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/0206038Orig1s000ClinPharmR.pdf. Accessed 29 Jun 2024."},{"issue":"1","key":"1507_CR56","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3390\/pharmaceutics15010162","volume":"15","author":"ME Ritivoiu","year":"2023","unstructured":"Ritivoiu ME, Dr\u0103goi CM, Matei D, Stan IV, Nicolae AC, Craiu M, Dumitrescu IB, Ciolpan AA. Current and future therapeutic approaches of exocrine pancreatic insufficiency in children with cystic fibrosis in the era of personalized medicine. Pharmaceutics. 2023;15(1):162. https:\/\/doi.org\/10.3390\/pharmaceutics15010162.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1507_CR57","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/thoraxjnl-2011-200393","volume":"67","author":"JP Clancy","year":"2012","unstructured":"Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012;67(1):12\u20138. https:\/\/doi.org\/10.1136\/thoraxjnl-2011-200393.","journal-title":"Thorax"},{"key":"1507_CR58","unstructured":"Therapeutic Goods Administration. Australian public assessment report for lumacaftor\/ivacaftor. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-lumacaftor-ivacaftor-160908-pi.pdf. Assessed 11 Oct 2024."},{"key":"1507_CR59","unstructured":"Vertex Pharmaceuticals Inc. Highlights of prescribing information for Orkambi (lumacaftor\/ivacaftor). https:\/\/pi.vrtx.com\/files\/uspi_lumacaftor_ivacaftor.pdf. Assessed on 25 Nov 2024."},{"key":"1507_CR60","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s43094-021-00254-y","volume":"7","author":"M Donakonda","year":"2021","unstructured":"Donakonda M, Indrakanti S, Pasala P, et al. A rapid RP-HPLC method for the simultaneous estimation of ivacaftor and tezacaftor and in silico study of their metabolitic products. Futur J Pharm Sci. 2021;7:118. https:\/\/doi.org\/10.1186\/s43094-021-00254-y.","journal-title":"Futur J Pharm Sci"},{"issue":"8","key":"1507_CR61","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3390\/pharmaceutics14081674","volume":"14","author":"E Choong","year":"2022","unstructured":"Choong E, Sauty A, Koutsokera A, Blanchon S, Andr\u00e9 P, Decosterd L. Therapeutic drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now? Pharmaceutics. 2022;14(8):1674. https:\/\/doi.org\/10.3390\/pharmaceutics14081674.","journal-title":"Pharmaceutics"},{"key":"1507_CR62","doi-asserted-by":"publisher","unstructured":"Tsai A, Wu SP, Haseltine E, Kumar S, Moskowitz SM, Panorchan P, Shah. Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor\/Tezacaftor\/Ivacaftor. Pulmonary therapy. 2020;6(2):275\u2013286. https:\/\/doi.org\/10.1007\/s41030-020-00124-7.","DOI":"10.1007\/s41030-020-00124-7"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01507-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01507-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01507-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T14:56:38Z","timestamp":1750690598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01507-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1507"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01507-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"30 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors. Competing interests: Femke A. Elzinga, Onno H. Akkerman, Bart L. Rottier, Hester van der Vaart, and\u00a0Daan J. Touw declare that they have no financial or nonfinancial interests that are directly or indirectly related to the work submitted for publication. Paola Mian acknowledges receiving\u00a0grant support from Vrienden Beatrix Kinderziekenhuis, unrelated to\u00a0the submitted work.\u00a0Gerard H. Koppelman discloses grant support from the Netherlands Lung Foundation, ZonMW (Vici grant), Ubbo Emmius Foundation, Teva the Netherlands, Vertex, and GSK, all outside the submitted work (money to institution); his institution received financial support for consultancy or invited presentations from Astra Zeneca, Sanofi, and Boehringer Ingelhei, outside the submitted work. Paul Malik is a full-time employee of Ionis Pharmaceuticals Inc. and may hold stock or stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data can be accessed upon reasonable request through the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"F.E. contributed to the literature search, data extraction, data analysis, and the writing of the initial draft of the manuscript. P.Ma. contributed to the conceptualization of the study, data analysis, and the writing and revision of the manuscript. O.A., B.R., and H.V. contributed to the revision of the manuscript. G.K. and D.T. contributed to the conceptualization of the study and reviewing the manuscript. P.Mi. contributed to the conceptualization of the study, literature search, data extraction, data analysis, and the writing and revision of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}